Rutgers Receives $6 million in Funding
News Jun 05, 2015
The funds from Janssen, a unit of New Brunswick-based Johnson & Johnson, one of the world’s largest health care companies, will increase research and development at theRutgers Engineering Research Center for Structured Organic Particulate Systems over the next several years.
The center is helping Janssen and other pharmaceutical companies implement a technique called continuous manufacturing that is expected to revolutionize the industry in the coming years and enable companies to deliver the latest medications to patients more quickly, with higher quality and potentially even at lower cost.
Continuous manufacturing, one of the more significant advances in pharmaceutical manufacturing in decades, is important because it is more efficient and less expensive than conventional methods to produce tablets and can help companies introduce new products faster while improving quality control.
“Continuous manufacturing represents the future of advanced pharmaceutical manufacturing,” said Fernando J. Muzzio, professor II, Department of Chemical and Biochemical Engineering. “With this latest funding, our center is now better positioned than ever to serve the scientific community, pharmaceutical companies and the regulatory agencies as the industry moves to this new process over the next decade.”
Muzzio directs the Engineering Research Center on Structured Organic Particulate Systems (C-SOPS), established at Rutgers nine years ago with funding from the National Science Foundation and a consortium of more than 40 companies within the pharmaceutical sector. It is the world’s largest academic-based research organization dedicated to modernizing pharmaceutical manufacturing.
The center brings together leading researchers from Rutgers and three partners – the New Jersey Institute of Technology, Purdue University and the University of Puerto Rico at Mayaguez – to work with industry leaders and the U.S. Food and Drug Administration, which would need to approve these manufacturing changes.
Pharmaceutical companies have not changed the basic way they manufacture tablets for decades. Raw materials are mixed in large batches, with a final step of pressing material into the shape of tablets. The new method involves feeding these raw materials into a continuously running process. The change is similar to what happened in the automobile industry when cars used to be built one at a time before the introduction of the assembly line. The new system requires a smaller facility, minimizes waste and allows for continuous quality monitoring.
As part of this collaboration begun five years ago, Rutgers engineers designed and built one of the first full production-scale continuous manufacturing facilities inside an engineering building on the Piscataway campus. This is being used as the model for a Janssen production line in Puerto Rico that is transitioning to continuous manufacturing, pending FDA approval, and as a model for other pharmaceutical manufacturers. When the line is operating, tablets pass through a series of tubes attached to a two-story tall structure. The tablets are for testing only and are not for patients.
“Continuous manufacturing is expected to replace conventional batch processing in the pharmaceutical industry as it has in many other industries, from food to steel production,” said Munzio. “But it will take time and extensive collaboration between government and industry, and that is where our work plays such an important role.”
While pharmaceutical companies have been slow to adopt this technology, the pace has accelerated in recent years following explicit support from the FDA. Janet Woodcock, director of the FDA’s Center for Drug Evaluation and Research and a leading advocate for the manufacturing change, recently attended an industry workshop at Rutgers to discuss this and other initiatives.
“Our collaboration with the Rutgers Engineering School has been very productive in helping us to prepare for the future by delivering the highest quality medicines in the most efficient way,” said Mauricio Futran, vice president, advanced technology, Janssen Manufacturing & Technical Operations. “We look forward to continuing to work closely with Rutgers and with regulators on the advancement and implementation of this important manufacturing technology.”
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
Improving Pharmaceuticals: Catalyst Specifically Tuned to Integrate Fluorine AtomsNews
In the race to create more potent and stable medicines, scientists know that adding fluorine can improve drug molecules. However, there is only one fluorination reaction known to occur in nature which is performed by complex and highly specialized enzymes that are difficult to replicate. Now, scientists have developed a new, streamlined molecule that can do the work of enzymes but be designed and controlled minutely.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018